iRadimed Corporation (NASDAQ:IRMD) Short Interest Up 25.1% in December

iRadimed Corporation (NASDAQ:IRMD) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 388,071 shares, an increase of 25.1% from the December 15th total of 310,250 shares. Approximately 4.8% of the company’s stock are sold short. Based on an average daily volume of 79,534 shares, the short-interest ratio is currently 4.9 days. Based on an average daily volume of 79,534 shares, the short-interest ratio is currently 4.9 days. Approximately 4.8% of the company’s stock are sold short.

iRadimed Trading Down 0.6%

IRMD traded down $0.57 during trading on Monday, hitting $102.00. The stock had a trading volume of 67,470 shares, compared to its average volume of 68,618. The firm has a market cap of $1.30 billion, a PE ratio of 61.82 and a beta of 1.09. iRadimed has a 12 month low of $47.48 and a 12 month high of $103.06. The company has a 50 day simple moving average of $94.73 and a 200-day simple moving average of $78.78.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, sell-side analysts anticipate that iRadimed will post 1.66 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Analyst Ratings Changes

Several research firms have commented on IRMD. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Capital set a $90.00 target price on shares of iRadimed in a research report on Friday, October 31st. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Finally, Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $87.33.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $97.45, for a total value of $487,250.00. Following the transaction, the chief executive officer directly owned 2,272,500 shares of the company’s stock, valued at $221,455,125. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the sale, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,000 shares of company stock worth $5,451,200 in the last 90 days. Corporate insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several large investors have recently bought and sold shares of IRMD. CWM LLC grew its position in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP bought a new stake in shares of iRadimed in the third quarter valued at about $40,000. Tower Research Capital LLC TRC grew its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares in the last quarter. State of Alaska Department of Revenue bought a new position in iRadimed during the third quarter valued at about $47,000. Finally, Spire Wealth Management acquired a new position in iRadimed in the 2nd quarter valued at approximately $60,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.